Hepatitis C

Referencias

Artículos principales

American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. October 2021 [internet publication].Texto completo

Artículos de referencia

1. Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015 Dec;44(4):717-34. Resumen

2. Dultz G, Zeuzem S. Hepatitis C virus: a European perspective. Gastroenterol Clin North Am. 2015 Dec;44(4):807-24. Resumen

3. Dan YY, Lim SG. Hepatitis C: an Eastern perspective. Gastroenterol Clin North Am. 2015 Dec;44(4):793-805. Resumen

4. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997 Sep;26(3 Suppl 1):15-20S. Resumen

5. Alter MJ, Margolis HS, Krawczynski K, et al; The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992 Dec 31;327(27):1899-905. Resumen

6. World Health Organization. Fact sheets: hepatitis C. July 2021 [internet publication].Texto completo

7. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015 Jan;61(1):77-87.Texto completo  Resumen

8. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45-57.Texto completo  Resumen

9. Nouroz F, Shaheen S, Mujtaba G, et al. An overview on hepatitis C virus genotypes and its control. Egypt J Med Hum Gen. 2015 Oct;16(4):291-8.Texto completo

10. Ryerson AB, Schillie S, Barker LK, et al. Vital signs: newly reported acute and chronic hepatitis C cases - United States, 2009-2018. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):399-404.Texto completo  Resumen

11. Centers for Disease Control and Prevention. Viral hepatitis surveillance report 2019: hepatitis C. May 2021 [internet publication].Texto completo

12. UK Health Security Agency. Hepatitis C in England and the UK. March 2022 [internet publication].Texto completo

13. World Health Organization. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec. 1999 Dec 10;74(49):425-7.Texto completo  Resumen

14. Mahowald MK, Larney S, Zaller ND, et al. Characterizing the burden of hepatitis C infection among entrants to Pennsylvania state prisons, 2004 to 2012. J Correct Health Care. 2016 Jan;22(1):41-5.Texto completo  Resumen

15. Jin F, Dore GJ, Matthews G, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):39-56. Resumen

16. Ly KN, Jiles RB, Teshale EH, et al. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. 2017 Jun 6;166(11):775-82. Resumen

17. Dugan E, Blach S, Biondi M, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):169-84.Texto completo  Resumen

18. World Health Organization. Global hepatitis report, 2017. April 2017 [internet publication].Texto completo

19. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1-16. Resumen

20. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S93-8. Resumen

21. Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ, et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:173-7. Resumen

22. Indolfi G, Nesi A, Resti M. Intrafamilial transmission of hepatitis C virus. J Med Virol. 2013 Apr;85(4):608-14. Resumen

23. Gerlach JT, Diepolder HM, Zachoval R. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003 Jul;125(1):80-8. Resumen

24. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004 Feb;12(2):96-102. Resumen

25. Smith JA, Aberle JH, Fleming VM, et al. Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis. 2010 Dec 15;202(12):1770-9.Texto completo  Resumen

26. World Health Organization. WHO best practices for injections and related procedures toolkit. March 2010 [internet publication].Texto completo  Resumen

27. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996 May;86(5):655-61.Texto completo  Resumen

28. Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017 Sep 18;(9):CD012021.Texto completo  Resumen

29. Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003 Nov;10(6):412-8. Resumen

30. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct 8;461(7265):798-801. Resumen

31. Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis. 2006 Jan 1;42(1):82-91. Resumen

32. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005 Jan-Feb;18(1):52-61. Resumen

33. Puro V, Petrosillo N, Ippolito G; Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Am J Infect Control. 1995 Oct;23(5):273-7. Resumen

34. Jafari S, Copes R, Baharlou S, et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010 Nov;14(11):e928-40. Resumen

35. Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol. 2001 Nov;96(11):3138-41. Resumen

36. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013 Mar;57(3):881-9.Texto completo  Resumen

37. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology. 2001 Aug;34(2):223-9. Resumen

38. Seeff LB. Natural history of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):21-28S. Resumen

39. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma Syringe Exchange Program. Am J Public Health. 1995 Nov;85(11):1531-7.Texto completo  Resumen

40. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999 Mar;29(3):908-14. Resumen

41. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20(1):17-35. Resumen

42. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002 Nov;36(5 Suppl 1):S3-20. Resumen

43. Hézode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008 Feb;134(2):432-9.Texto completo  Resumen

44. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008 Jan;6(1):69-75.Texto completo  Resumen

45. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. October 2021 [internet publication].Texto completo

46. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007 Nov;102(11):2589-600. Resumen

47. Calvaruso V, Cammà C, Di Marco V, et al. Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. J Viral Hepat. 2010 Jul;17(7):469-74. Resumen

48. Centers for Disease Control and Prevention. Hepatitis C, acute 2020 case definition. April 2021 [internet publication].Texto completo

49. Centers for Disease Control and Prevention. Hepatitis C, chronic 2020 case definition. April 2021 [internet publication].Texto completo

50. Public Health England. Public Health England encourages hepatitis C testing. Jul 2017 [internet publication].Texto completo

51. Galbraith JW, Anderson ES, Hsieh YH, et al. High prevalence of hepatitis C infection among adult patients at four urban emergency departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017. MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-74.Texto completo  Resumen

52. US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 Mar 2;323(10):970-5.Texto completo  Resumen

53. Schillie S, Wester C, Osborne M, et al. CDC recommendations for hepatitis C screening among adults - United States, 2020. MMWR Recomm Rep. 2020 Apr 10;69(2):1-17.Texto completo  Resumen

54. Centers for Disease Control and Prevention. Screening for viral hepatitis during the domestic medical examination of newly arrived refugees. October 2020 [internet publication].Texto completo

55. Marks K, Naggie S. Management of hepatitis C in 2019. JAMA. 2019 May 17;322(4):355-6. Resumen

56. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017 Sep 18;(9):CD012143.Texto completo  Resumen

57. Powderly WG, Naggie S, Kim AY, et al. IDSA/AASLD response to Cochrane review on direct-acting antivirals for hepatitis C. Clin Infect Dis. 2017 Dec 1;65(11):1773-5.Texto completo  Resumen

58. European Association for the Study of the Liver. Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C. J Hepatol. 2017 Oct;67(4):663-4.Texto completo  Resumen

59. Jakobsen JC, Nielsen EE, Koretz RL, et al. Do direct acting antivirals cure chronic hepatitis C? BMJ. 2018 May 10;361:k1382. Resumen

60. Carrat F, Fontaine H, Dorival C, et al; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019 Feb 11;393(10179):1453-64. Resumen

61. Mendizabal M, Piñero F, Ridruejo E, et al. Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2554-63.e3. Resumen

62. US Food and Drug Administration. FDA drug safety communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. October 2016 [internet publication].Texto completo

63. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017 May 2;166(9):637-48.Texto completo  Resumen

64. US Food and Drug Administration. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. October 2015 [internet publication].Texto completo

65. US Food and Drug Administration. FDA drug safety communication: FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. August 2019 [internet publication].Texto completo

66. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21.Texto completo  Resumen

67. Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2015 Mar;4(1):137-44.Texto completo  Resumen

68. van der Ree MH, de Vree JM, Stelma F, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017 Feb 18;389(10070):709-17. Resumen

69. Centers for Disease Control and Prevention. National progress report 2025 goal: reduce reported rate of hepatitis C-related deaths by ≥20%. August 2020 [internet publication].Texto completo

70. Fattovich G, Guistina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 Feb;112(2):463-72. Resumen

71. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998 Dec;28(6):1687-95. Resumen

72. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis: a study of 200 patients. J Hepatol. 2004 May;40(5):823-30. Resumen

73. Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute clinical practice update - expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017 May;152(6):1578-87.Texto completo  Resumen

74. Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009 May;104(5):1147-58. Resumen

75. Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US veterans with HCV. Hepatology. 2014 Jul;60(1):98-105. Resumen

76. Innes H, McAuley A, Alavi M, et al. The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: a population cohort-study. Hepatology. 2018 Jan;67(1):97-107. Resumen

77. European Medicines Agency. PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C. December 2016 [internet publication].Texto completo

78. Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-80. Resumen

79. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002 Jan;55(1):4-13. Resumen

80. Montero N, Favà A, Rodriguez E, et al. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev. 2018 May 7;(5):CD011403.Texto completo  Resumen

81. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993 Feb 18;328(7):465-70.Texto completo  Resumen

82. Wilson SE, Lee WM, Murakami C, et al. Mooren-type hepatitis C virus-associated corneal ulceration. Ophthalmology. 1994 Apr;101(4):736-45. Resumen

83. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999 Apr;29(4):1311-6. Resumen

84. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis. 1999;19(3):263-9. Resumen

85. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745-50. Resumen

86. Molina-Cuadrado E, Mateo-Carrasco H, Collado A, et al. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. Eur J Hosp Pharm. 2018 May;25(3):132-7.Texto completo  Resumen

87. Medicines and Healthcare products Regulatory Agency. Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes. December 2018 [internet publication].Texto completo

88. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C RNA and histological lesions in chronic HCV. Hepatology. 1998 Jun;27(6):1717-22. Resumen

89. Terrault NA. Sexual activity as a risk factor for HCV infection. Hepatology. 2002 Nov;36(5 Suppl 1):S99-105. Resumen

90. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39.Texto completo  Resumen

91. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010 Oct;52(4):1497-505. Resumen

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad